Payment overview · 2025
General Payments
$1,330.69
78 reported records · 17 companies
Healthcare provider profile · identity verified
Ronald Duncan, MD
Allopathic & Osteopathic Physicians|Emergency Medicine · ELWOOD, IN · NPI 1629090980
Verified facts
What the public records show
CMS Open Payments records show Ronald Duncan, MD received $1,330.69 in general payments during 2025 across 78 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $235.64 | 17.7% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $171.93 | 12.9% | 13 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $161.05 | 12.1% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $155.36 | 11.7% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $144.55 | 10.9% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $102.03 | 7.7% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $80.87 | 6.1% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $56.19 | 4.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.34 | 3.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.09 | 2.5% | 2 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $31.57 | 2.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.77 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.50 | 1.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.17 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.97 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.66 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.00 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,316.03 | 77 |
| Education | $14.66 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $161.05 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $144.55 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $132.71 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $131.21 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $102.03 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $87.58 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $86.09 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $80.87 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $69.27 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $69.27 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $67.81 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $56.19 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $51.34 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $33.09 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.35 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.24 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.77 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.96 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.96 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.96 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 39 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 190 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 76 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 114 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
166 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
39 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 693 | 198 |
| Gabapentin | Gabapentin | 468 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 440 | 129 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 431 | 108 |
| Lisinopril | Lisinopril | 401 | 124 |
| Metoprolol Succinate | Metoprolol Succinate | 366 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 329 | 56 |
| Metformin Hcl | Metformin Hcl | 321 | 85 |
| Omeprazole | Omeprazole | 295 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 216 | 58 |
| Sertraline Hcl | Sertraline Hcl | 216 | 56 |
| Alprazolam | Alprazolam | 210 | 33 |
| Potassium Chloride | Potassium Chloride | 209 | 50 |
| Losartan Potassium | Losartan Potassium | 207 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 200 | 57 |
| Eliquis | Apixaban | 190 | 38 |
| Trazodone Hcl | Trazodone Hcl | 187 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 181 | 57 |
| Furosemide | Furosemide | 179 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 172 | 62 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 169 | 45 |
| Ozempic | Semaglutide | 166 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 51 |
| Meloxicam | Meloxicam | 143 | 44 |
| Tramadol Hcl | Tramadol Hcl | 141 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 36 |
| Simvastatin | Simvastatin | 133 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 129 | 33 |
| Naproxen | Naproxen | 129 | 27 |
| Pregabalin | Pregabalin | 129 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 122 | 40 |
| Buspirone Hcl | Buspirone Hcl | 120 | 26 |
| Metformin Hcl Er | Metformin Hcl | 119 | 38 |
| Jardiance | Empagliflozin | 114 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 112 | 34 |
| Allopurinol | Allopurinol | 108 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 30 |
| Montelukast Sodium | Montelukast Sodium | 92 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | 22 |
| Carvedilol | Carvedilol | 91 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 25 |
| Clonazepam | Clonazepam | 79 | 13 |
| Alendronate Sodium | Alendronate Sodium | 77 | 23 |
| Farxiga | Dapagliflozin Propanediol | 76 | 15 |
| Glimepiride | Glimepiride | 76 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 22 |
| Torsemide | Torsemide | 75 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 19 |
| Methocarbamol | Methocarbamol | 69 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 68 | 14 |
| Prednisone | Prednisone | 67 | 48 |
| Lorazepam | Lorazepam | 64 | 13 |
| Meclizine Hcl | Meclizine Hcl | 63 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 17 |
| Famotidine | Famotidine | 59 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 16 |
| Donepezil Hcl | Donepezil Hcl | 57 | 12 |
| Ibuprofen | Ibuprofen | 54 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 14 |
| Atenolol | Atenolol | 52 | 16 |
| Topiramate | Topiramate | 52 | 15 |
| Levetiracetam | Levetiracetam | 48 | 11 |
| Trulicity | Dulaglutide | 48 | 11 |
| Lovastatin | Lovastatin | 47 | 13 |
| Ondansetron Odt | Ondansetron | 46 | 17 |
| Finasteride | Finasteride | 45 | 18 |
| Primidone | Primidone | 44 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Aripiprazole | Aripiprazole | 42 | 13 |
| Estradiol | Estradiol | 42 | suppressed |
| Nystatin | Nystatin | 42 | 18 |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Nitroglycerin | Nitroglycerin | 40 | 20 |
| Tradjenta | Linagliptin | 40 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 39 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 30 |
| Cephalexin | Cephalexin | 37 | 33 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 20 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Baclofen | Baclofen | 34 | 11 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Klor-Con M20 | Potassium Chloride | 32 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 13 |
| Cefdinir | Cefdinir | 29 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 11 |
| Bupropion Hcl | Bupropion Hcl | 27 | 12 |
| Linzess | Linaclotide | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 26 | 26 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 18 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Glucagon Emergency Kit | Glucagon | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Forteo | Teriparatide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,330.69 · 78 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Ohtuvayre, PREVNAR 20, QULIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error